GLYATL3 Inhibitors
GLYATL3 inhibitors are a class of compounds that specifically target and inhibit the activity of the enzyme glycine N-acyltransferase-like 3 (GLYATL3). This enzyme belongs to the glycine N-acyltransferase (GLYAT) family, which is involved in the process of conjugating glycine to acyl-CoA derivatives, facilitating the formation of N-acylglycine compounds. GLYATL3 inhibitors typically interact with the active site or other crucial domains of the enzyme, reducing or completely blocking its catalytic activity. The structure of GLYATL3 allows for selective inhibition, making the design of these inhibitors quite specific. Compounds designed as GLYATL3 inhibitors often possess functional groups that can effectively bind to the enzyme's active site or modify its conformation to render it inactive. These inhibitors may include a variety of chemical backbones, such as small organic molecules or peptides, which are tailored to achieve high specificity and binding affinity to GLYATL3.
Structurally, the inhibitors of GLYATL3 are developed to exhibit a balance of hydrophobic and hydrophilic properties to ensure optimal interaction with the enzyme while maintaining stability and solubility in biological systems. Common structural motifs in these inhibitors may include amide bonds, aromatic rings, and other functional groups conducive to forming hydrogen bonds or van der Waals interactions within the enzyme's binding pocket. Such design considerations are crucial for ensuring that the inhibitor can effectively compete with natural substrates of GLYATL3. While the specificity of these inhibitors is generally high, slight modifications in their chemical structure can significantly impact their potency and selectivity. The study and development of GLYATL3 inhibitors not only help elucidate the biochemical pathways involving glycine conjugation but also enhance the understanding of how this enzyme functions at a molecular level, providing insight into its role in metabolism and cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A 922500 | 959122-11-3 | sc-203793 | 10 mg | $270.00 | 2 | |
FASN inhibitor affecting de novo lipogenesis. A922500 inhibits FASN, influencing lipid metabolism pathways. While not directly targeting GLYATL3, alterations in lipid metabolism may indirectly impact its function in glycine-N-acyltransferase activity within the mitochondrion. | ||||||
CB 839 | 1439399-58-2 | sc-507354 | 10 mg | $140.00 | ||
Glutaminase inhibitor affecting glutamine metabolism. CB-839 inhibits glutaminase, impacting glutamine utilization. As GLYATL3 may be involved in mitochondrial processes, altering glutamine metabolism might indirectly influence glycine-N-acyltransferase activity within the mitochondrion. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
AMPK activator affecting energy homeostasis. Epigallocatechin gallate activates AMPK, influencing cellular energy status. Indirectly, this could affect mitochondrial functions, potentially modulating GLYATL3 activity in glycine-N-acyltransferase within the mitochondrion. | ||||||
(+)-Etomoxir sodium salt | 828934-41-4 | sc-215009 sc-215009A | 5 mg 25 mg | $151.00 $506.00 | 3 | |
CPT1 inhibitor affecting fatty acid oxidation. Etomoxir inhibits CPT1, influencing fatty acid metabolism. While not directly targeting GLYATL3, alterations in fatty acid oxidation may indirectly impact its role in glycine-N-acyltransferase activity within the mitochondrion. | ||||||
6-Diazo-5-oxo-L-norleucine | 157-03-9 | sc-227078 sc-227078A sc-227078B sc-227078C | 5 mg 25 mg 100 mg 250 mg | $88.00 $291.00 $926.00 $2195.00 | ||
Glutamine antagonist affecting glutamine metabolism. 6-Diazo-5-oxo-L-norleucine inhibits multiple enzymes in glutamine metabolism. Given GLYATL3's mitochondrial location, interfering with glutamine metabolism might indirectly affect its function in glycine-N-acyltransferase activity. | ||||||
UK 5099 | 56396-35-1 | sc-361394 sc-361394A | 10 mg 50 mg | $236.00 $987.00 | 5 | |
MCT1 inhibitor affecting lactate transport. UK5099 inhibits MCT1, impacting lactate transport. While not directly targeting GLYATL3, modulation of lactate transport may indirectly influence mitochondrial functions, potentially altering glycine-N-acyltransferase activity within the mitochondrion. | ||||||
C75 (racemic) | 191282-48-1 | sc-202511 sc-202511A sc-202511B | 1 mg 5 mg 10 mg | $72.00 $206.00 $290.00 | 9 | |
FASN inhibitor affecting de novo lipogenesis. C75 inhibits FASN, influencing lipid metabolism pathways. While not directly targeting GLYATL3, alterations in lipid metabolism may indirectly impact its function in glycine-N-acyltransferase activity within the mitochondrion. | ||||||
STF 31 | 724741-75-7 | sc-364692 | 10 mg | $187.00 | 3 | |
SLC19A1 inhibitor affecting cellular folate uptake. STF-31 inhibits SLC19A1, influencing folate transport. As GLYATL3 is predicted to be involved in glycine-N-acyltransferase activity, modulating cellular folate availability may indirectly affect its function in this metabolic process within the mitochondrion. | ||||||
Phenformin Hydrochloride | 834-28-6 | sc-219590 | 10 g | $119.00 | 4 | |
AMPK activator affecting energy homeostasis. Phenformin activates AMPK, influencing cellular energy status. Indirectly, this could affect mitochondrial functions, potentially modulating GLYATL3 activity in glycine-N-acyltransferase within the mitochondrion. | ||||||
Lonidamine | 50264-69-2 | sc-203115 sc-203115A | 5 mg 25 mg | $105.00 $364.00 | 7 | |
Mitochondrial hexokinase inhibitor affecting ATP production. Lonidamine inhibits mitochondrial hexokinase, impacting ATP generation. As GLYATL3 is located in the mitochondrion, modulating ATP production may indirectly influence its role in glycine-N-acyltransferase activity within this organelle. | ||||||